By the end of 2015, Norwegian molecular diagnostics firm Genetic Analysis hopes to have a microarray-based test for diagnosing dysbiosis in irritable bowel syndrome patients cleared for clinical use in both Europe and the US.

CEO Kari Stenersen told BioArray News this week that the Oslo-based firm anticipates CE-IVD marking the test next month, with a planned submission to the US Food and Drug Administration anticipated in the first quarter of 2015, followed by clearance at the end of that year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.